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CHAPTER

I

INTRODUCTION

Six-mercaptopurine (6-MP) is an analogue of the nucleic
acid constituents adenine and the purine base hypoxanthine.
This compound is believed to interfere with biosynthesis of
the aforementioned acids and is metabolized in the body to
6-thiouric acid (6-mercapto 2, 8-purinediol) (1) and it has
been used in the treatment of acute leukemia and chronic
myelogenous leukemia.

Studies have shown that 6-MP will reduce

the leukocyte count but not without some toxicity.

Various

experimental techniques have established the feasibility of
6-MP as a chemotherapeutical agent in the treatment and possible control of such diseases as leukemia, tumors, hepatic
disorders, etc .

The toxicity of pure 6-MP has been compared

with that of 6-mercaptopurine-palladium complex to determine
if the metallic complex would cause a reduction in leukocyte
count without the toxicity generally associated with 6-MP
administration.

Considerable study has been conducted using

6-MP in chicks, rats, mice and dogs but only a minimum amount
of study has been done utilizing non-human primates.

Six-

mercaptopurine investigations in man have been limited for

-
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obvious reasons and the possibility of using such an agent
effectively and safely in the human species deserves more
extensive consideration with subjects as closely related to
man as possible .

Lewis and co-workers at Prairie View A.

and M. College initiated investigations using marmosets , a
species of primates in 1969.

Several advantages were associ-

ated with this investigation; namely, the marmosets were
readily obtained from a research group currently using this
species in other studies; they were small enough to be
housed and handled fairly easily; and they represented a
close relationship to man with which 6-MP toxicity data could
be correlated.

Consequently, an objective of this study was

to determine the feasibility of utilizing the marmoset as an
experimental species in t he search for an effective non-toxic
leukopenia-inducing compound.

Essential to the actual ex-

perimentation was the development of a suitable method of
administering the selected oral doses of 6-MP and 6-MP-palladium
complex.

The methods attempted, the method finally accepted

and the results of the experimentation with regard to the
leukopenia induction capacity of 6-MP palladium complex in the
non-human primate are reported herein.

CHAPTER

II

REVIEW OF LITERATURE
Clinically, 6-MP is used in the treatment of acute leukemia
and chronic myelogenous leukemia, generally providing temporary
remission (1).

The average dose in the human is between 2.5 and

5 mg/kg per day by individualized oral administration (1).
Leukopenia may occur with average doses and large doses may produce thrombocy topenia, anemia, hepatic necrosis, ulceration of
G. I. tract, nausea, vomiting and anorexia (1).

This dose is

tolerated for several weeks by most patients and may be increased
if there is not clinical improvement after four weeks.

Blood

counts are usually taken at weekly or more frequent intevals
(1).

At the first sign of abnormal depression of bone narrow,

administration of 6-MP is usually discontinued or the dosage
level immediately reduced (1).

In the presence of impaired renal

function it is advisable to give a smaller initial dose and to
increase with caution (2).
TOXICITY AND ANTILEUKEMIC ACTION IN VARIOUS SPECIES

~.

Goldin et . al. (2), reported that 6-MP appeared to

act as an antimetabolite in the whole animal but reduction in
toxicity could be obtained by appropriate administration of
various metabolities .

The lethal toxicity of 6-MP was diminished
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by prior administration of each of the following:

guanylic

acid, adenylic acid, adenosine, guanosine, inosine, diphosphopyridine nucleotide (DPN), ATP, RNA, DNA, Na-DNAate and thymidine.
The weight loss associated with 6-MP toxicity was reduced when
animals were protected by administration of various metabolites.
On concomitant administration of various metabolites, as well as
prior administration, the toxicity of 6- MP was dependent on
relative doses of inhibitor and metabolite employed.

Goldin et.

al. (2) found that an increase in 6-MP dosage yielded an increase
in mortality.

The extent of toxicity was subject to the temporal

relationships existing between the metabolite and antimetabolite.
The effective metabolites protected well when administered prior
to or simultaneously with 6-MP.

However, the action of 6-MP was

apparently quite rapid and relatively irreversible.

The

metabolites investigated showed a marked reduction in their
ability to protect when the drugs were withheld for two to four
hours following administration of 6-MP.

These results were in

agreement with the observation of Elion et al . (3), who observed that upon administration of labeled 6-mercaptopurine,
the peak of activity in most tissues of the mouse occurred in
two to three hours.

The dose-mortality relationshi p with

6-MP administered alone and with the metabolite appeared to
be similar in mice with and without tumors.

Goldin (2) and

his associates also found that the specific antileukemic action
of 6-MP could be increased by appropriate schedules of treatment.

-

Dogs.
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The toxicity of 6-MP in dogs appeared to be about

equally active whether given intravenously or per os and the
clinical course was similar by either route (4).

Among the

effects observed included anorexia, loss of weight, diarrhea,
often becoming hemmorrhagic in animals given fatal doses,
jaundice, elevation of the hematocrit , and hypochloremia.
latter two were attirubted to diarrhea and dehydration.

The
In

addition, hyperbilirubinernia and an associated increase in
bromsulfalein retention was observed.
served.

Leukopenia was also ob-

Hemorrhagic diarrhea that developed in dogs given

fatal doses of 6-MP was associated with intestinal lesions (4).
Man.

Six-mercaptopurine induced temporary remissions in

acut e leukemia in both children and adults and also ameliorated
patients afflicted with chronic myeloid leukemia (5).

Six-MP,

labeled in the 6-position with s-35 , when given to an adult
with chronic myeloid leukemia, evidenced the following results
from a study of its distribution and metabolism:

1) rapid

metabolism of the drug in child and adult; 2) decline of
activity in the blood of both (activity in the plasma declined
below that in whole blood) ; 3) the half-life of 6-MP in the
blood was calculat ed at 90 minutes; 4) significant radioactivity in the cerebrospinal fluid after 30 minutes; 5) 60%
of the radioactivity recovered in the urine after 24 hours;
6) chromatograms of the urine showed the presence of 6-thiouric
acid , Rf

o. 25 ,

G-MP, Rf

o.40,

an unknown metabolite, Rf 0.70

- 6 -

and sulfate Rf 0.90.

The radioactivities found in the spinal

fluid of the child and the adult indicated that 6-MP at a
dosage of 6 mg/kg; given intravenously, passed the bloodbrain barrier (5).

The results did not establish that this

happened when dosages of 2.5 mg/kg or 5 mg/kg were given
orally.

Studies on the oral administration of 6-MP-6-S35

shows significant radioactivity in the spinal fluid at four
hours after a 6 mg/kg dosage level by the oral route.
appeared to penetrate the blood-brain barrier.

Six-MP

The urinary

findings in both the child and the adult indicated the rapid
and extensive transformations of 6-MP (5}.

Uric acid levels

were frequently elevated in leukemia, both in blood and in
the urine (5, 6}.

Uric acid excretion appeared to be an

indication of the effectiveness of drugs which either actually
killed cells or caused a decrease in the proliferation by
metabolic competitive inhibition (6}.
~.

Lewis et. al. (7-9) have conducted several investi-

gations on the immunosupressive activity of 6-MP and its
derivatives.

White leghorn cockerels were used to compare

the effects of 6-MP and the metallic complexes of this compound
(platinum and palladium) on homograft survival and leu.kopenia
induction capacity.

Their results showed that at equal dosage

levels, the leukopenia induction capacity of 6-MP, the
platinum complex and the palladium complex, was essentially
the same after a ten-day treatment period.

The platinum and

-
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palladium compelexes were less toxic, as demonstrated by greater
weight gain and lower mortality.

At equirnolar dosage levels,

results were similar to those observed when evaluation of
equal dosage levels was conducted.
Non-human Primates.

Non-human primates represent a

diversified and broad g roup consisting of some 80 genera and
250 species.

Thus, information on various parameters, in

general, and hematologic aspects in particular, has been
limited, s p otty and confined to a relatively few species (10.
Investigations involving rhesus and cytomolgus monkeys (10-13),
M. mutallo (14), and M. nernestrina monkeys have been conducted
comparing blood p ictures in man and monkey.

Rall and others

(15), in a National Cancer Institute cancer chemotherapy program designed to study quantitative toxicity data in man,
used anti-cancer drugs (including 6-MP) in monkeys, mice, rats,
and dogs with comparable results for man and monkey.
Use of 6-mercaptopurinato-metallo-Complexes.

Although

many studies have been reported with respect to 6-MP and its
other derivatives, there is a dearth of information in the
literature on the immunosuppressive activity of the metallic
complexes of 6-MP (7).

Among the studies reported are inves-

tigations concerned with the effects of the platinum complex
and palladium complex on skin homograft survival and the
comparative leukopenia-induction capacity of the complexes in
young chicks (7-9).

The results of such studies indicated

-
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the feasibility of using metallo-complexed 6-MP in the treatment of hematological disorders in man.

The work reported

to date justifies the continued study of these complexes and
emphasizes the need for further studies on the pharmacodynamics
of the immunosuppressive process.

Whatever mechanisms are

ultimately proposed, it is abundantly clear at present that
minor alterations in the structure of purines can give rise
to profound and unexpected changes in the pharmacologic
effects (3).

In conjunction with the opinions of many other

scientists, the writer feels that a species of primates closely
related to man should be used in future 6-mercaptopurinatometallo complex studies of hematological interactions.

In

view of the above, it is possible that the small, squirrel-like
marmosets (Hepalidae Family) of the primate order will prove to
be a suitable laboratory animal for studies of the nature
previously described.

CHAPTER

III

EXPERIMENTAL PROCEDURE
MATERIALS AND METHODS

Experimental Animals--Thirty-five marmosets; 31 of the
cotton top and 4 of the~• oedipus species were transferred
from the University of Texas Dental Research Institute,
Houston, Texas to the primate center at Prairie View A. and
M. College during May, 1969.

The animals along with others,

had been utilized by Dr. Barnett Levy and his colleagues at
the Institute for dentition studies.

Up-to-date case history

folders were provided with the animals.

The marmosets were

housed in small groups of not more than 3 per cage.

Weights

were recorded and 20 animals (10 males and 10 females), all
of the cotton top species, were selected for the experiments
based on weight similarity.

Metal tags bearing 3 digit code

numbers and worn around the animal's necks by chains were used
to identify the marmosets.

Codes ending in even integers

(e.g. "236") represented males while the numbers ending in
odd integers (e.g. "537") were used to code the females.
0

Ambient temperatures in the range of 75 to 85 F were maintained
by appropriate lowering or raising of the windows to conform to
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the animals' native therm.al environment.

From the 20 primates,

four groups of five animals each were designated as experimental
groups for the purpose of this study.

Three females and two

males comprised the control group, four males and one females
were used for a treatment group receiving pure 6-MP at 1mg of
6-MP per kilogram of body weight per day (lmg/kg/day).

A

third group of three males and two females formed the l mg.
6-MP-Palladiurn complex per kg/day treatment group.

The fourth

group receiving 2 mg of the complex per kg-day was made up of
five females.

All of the marmosets were maintained on a

prepared marmoset food (Science Diet)* and banana disks
averaging 10 mm. in width.
Handling and Conditioning--Workman's gloves were used
to catch the marmosets in the cages.

In attempts to avoid

capture, the animals scurried about the cage and caused an
increase in metabolic activity which interfered with normal
blood counts.

subsequently, two medium sized mesh cord nets

With short handles were used to catch and contain the animals.
These proved effective in catching the marmosets, saving time
and decreasing the excitement and frustration.

Two marmosets

were selected and an effort was made to extract blood from
the soles of the feet.

This method proved unsatisfactory

*Marmoset Food, "Science Diet," manu~a 7t~red and_marketed
~nder license by Institutional Products d1v1s1on of Hill Packing Company, Topeka, Kansas. 66601
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as the skin on the soles of the feet was difficult to penetrate with a needle.

Puncture of the femoral vein in the

hind leg, however, produced a sufficient flow of blood.
An acceptable method of administering oral doses of the
compounds was attempted.

A dose of methyl cellulose, (inert

ingredient) measured at 1.5 mg/kg of body weight for each
animal, was poured directly into the mouth and washed down
with distilled water.

This method proved unsatisfactory as

the animals choked on the methyl cellulose and regurgitated
it.
A suspension of the 6-MP and the metallic complex in
sugar solution introduced by means of a pipette was also
unsuccessfully attempted.

The marmosets were readily recep-

tive to sugar water given with the pipettes.

However, some

difficulty was experienced in suspending the compound in the
sugar solution, consequently this procedure was ineffective.
The use of light karo syrup as a suspension medium likewise
proved impractical.
The method finally successfully utilized involved the
use of banana slices split through the radii of the curved
plane with the compound inbedded between the halves.

Careful

preparation of the dosage slices reduced the possibility of
accidental waste and this method was subsequently used in
all oral administrations.
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· preparation of 6-Mercaptopurine-Palladium complex and
Dosage Mixtures--The 6-mercaptopurine-palladium complex was
prepared following the method of Kirschner (16).

The pre-

pared comp lex was mixed with methyl cellulose in a ratio of
one part 6-MP palladium complex to 100 parts methylcellulose.
Pure 6-MP doses were likewise mixed in a 1 to 100 ratio .

This

was done to permit accurate dosage measurements within the
sensitive range of the available scale to be weighed.

Dosage

weighings of the mixture varied between 30-50 milligrams.
Preparation of Turk's Diluting Fluid For White Blood Cell
Counts--A 1% ge ntian violet solution was prepared by dissolving
one gram reagent grade gentian violet powder in 100 ml distilled water.

Two ml of the solution was pipetted into a

beaker containing six ml glacial acetic acid and the mixture
was placed in a 200 mg flask and diluted to volume with distilled water (18) .
White Blood Cell Counts--White blood cell counts were
made using a clinical method (17).

Blood from the femoral

vein of the marmosets was drawn into two sterile pipettes to
the 0.5 mark.

The tip of each pipette was wiped dry and the

Volume exactly adjusted.
in to the 11 mark.

Turk's diluting fluid was drawn

The tips were wiped dry and each filled

pipette agitated on the pipette agitator for three minutes.
Several drops of diluent mixture were expelled and discarded.
One side of the hemacytometer was filled from each pipette.
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The cells were allowed to settle for approximately one minute
and then counted at lOX power on a binocular microscope.
The white blood cells in the four large corner squares of
each side of the hemacytometer was counted, including all
cells on the upper and left lines of squares counted.
on the lower and right lines were disregarded.

Cells

The number

of cells counted was multiplied by 25, the appropriate factor
accounting for volume and dilution, and the resulting cell
number per cubic millimeter of blood was recorded.
The above mentioned procedure was followed for the first
experimental group only.

After consideration, it was felt

that two blood samples from the same animal was not necessary
and only one pipette for each animal was used in the two
subsequent counts.

Accordingly, only one side of the

hemacytometer was used to make the leukocyte count.

The num-

ber of cells counted on the one side was rniltiplied by 50 ,
instead of 25, to give a similar reading as in the first
group .

CHAPTER

IV

RESULTS AND DISCUSSIONS

Data were collected on a series of experiments designed
to determine the leukopenia induction capacity of 6-MP
palladium complex in marmosets (Cotton top).

All treated

marmosets received the 6-MP palladium complex by oral administration daily at measured doses for each selected group
during the treatment period.
Leukocyte reduction was based on comparative white blood
cell counts of control and treated groups.

Table one (Experi-

ment I) shows the individual leukocyte counts of the control
and treated groups at pre-treatment and post-treatment with
doses of one mg/kg 6-MP palladium complex.

The members of

each group was selected according to comparable weights.
Four controls evidenced a decrease in leukocytes between the
initial and 10-day treatment period while one showed an increase.

Of the group receiving one mg of 6-MP per kilogram

of body weight (one mg/kg body wt-day), two animals registered
a decrease in count, two an increase and one remained constant between the initial and 10 days of treatment.

All five

marmosets given one mg per kilogram of 6-MP palladium complex
exhibited a decrease in leukocyte count over the same period.
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Table I.

Indivi ual weights and leukocyte counts (Experiment I).

.

Group

Initial • Initial
Sex. Weight . WBC
{g)
• Count**

1 mg/kg
6-MP

X

2 mg/kg
6pdx

• Weight (g)

Treatment
WBC
.•• 10-day
Count**

405
369
304
400
387

10,275
6,375
7,425
8,325
11,850

8,050
8,600
18,350
10,925
11,950

427
452
444

406
432

11,075
34,325
9,975
10,550
6,575

F
F

451
405
412
397

30,575
14,975
18,425
13,400
17,250

440
442
414
417
371

17,350
11,350
12,725
9,025
9,250

F
F
F
F
F

444
512
461
446
480

11,075
12,875
9,675
14,075
12,200

461
445
473
448
497

12,875
12,650
15,850
12,050
20,025

F
F

409
376
342

M

391
385

M
M

423
4 8

M
F

l mg/kg
6-MP
pd

10-day
• Treatment

12,725
17,275
11,800
11,025
9,500

F

Control

.

M
M
M

**Cells per cu. mm.

437
3 8
445

446
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Only one animal in the group administered two mg 6-MP palladium
complex showed a decrease, three evidenced an increase, and the
blood count of the remaining animal was constant during the
entire period.
The averages of weights and leukocyte counts for Experiment I are presented in Table 2.
represent averages.)

(All subsequent tables

Weights averaged 380 grns. in the controls

prior to treatment and 373 gms following 10 days of treatment.
The average of weights for the animals receiving one mg/kg 6-MP
were 428 gms. and 432 gm, before and after treatment, respectively.

The marmosets receiving one mg/kg 6-MP palladium com-

plex showed an initial average weight of 422 gms. and 417 grns.
after treatment in this experiment.

The group administered

two mg/kg 6-MP palladium complex decreased slightly in weight
from 468 grns. to 465 gms.
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Table 2.

Average of weight and leukocyte count (Experiment I).

Initial
Weight

Group

(g)

.
.

10-day

Treatment
Weight
(g)

Initial
Leukocyte
Count**

Leukocyte
Count**

10-day

Control

380

373

12,465

8,850

1 mg/kg
6-MP

428

432

11,575

14,500

422

417

18,925

12,060

468

465

11,980

14,690

1 mg/kg
6-MP

pd

2

X

mg/kg

6-MP pd

X

**Cells per cu. mm.

Initial white blood cell counts for the controls (Table 2}
averaged 12,465 while the count at 10 days averaged 8,i50.
Leukocyte counts for the one mg/kg 6-MP group averaged 11,575
and 14,SOO before and after treatment, respectively.

In the one

mg/kg 6-MP palladium complex group, leukocytes decreased from
18 ,925 initially to 12,060 at 10 days.

White blood cell counts

- 18 for the two mg/kg 6-MP palladium complex group increased from
11,980 to 14,690.
A second experiment was conducted and data were recorded
as follows:

pretreatment weights and leukocyte counts, 10

day treatment weight and leukocyte counts and 10 day post
treatment weight and leukocyte counts.
presented in Table 3.

These results are

The controls averaged 372 gms. by weight

initially, decreased to 363 gm. at 10 days and increased to
380 gms. at 10 days post treatment.

The marmosets treated

with one mg/kg of 6-MP averaged 418 gms., 450 gms . and 428 gms.
for each weighing, respectively.

In the group given one mg/kg

of 6-MP palladium complex, weights increased from 407 gms. to
427 gms. over the treatment period and decreased to 422 gms.
at post treatment.

Fluctuations in weight between 468 gms.

448 gms. and 463 gms. were observed for the group administered
two mg/kg 6-MP palladium complex.
Leukocyte counts for experiment 2 revealed interesting
Patterns.

counts for the control group were elevated from

8,850 to 13,015 between the initial and 10 day period of treatment, then decreased to 12,380 following 10 days post treatment.
In the group given one mg/kg 6-MP, blood counts varied from
1 2 , 400 to 8,055 to 14,500 respec t ive
. 1 Y•

Leukocytes increased

from 12,060 to 14 , 325 and decreased again to 12,l 4 0 over the
test period for the group administered one mg/kg 6-MP palladium

Table 3.

Average weight and leukocyte counts (Experiment II)

(Cotton-Top Species)

Initial
Weight
(g)

Group

10-day
10-day
Post
• Treatment .
• Treatment
Weight
Weight
(g)

.

Initial
Leukocyte
Count*

10-day
Treatment
. Leukocyte
Count*

10-day
Post
. Treatment
Leukocyte
Count*

.

(g)

Control

372

363

380

8,850

13,015

12,380

1 mg/kg
6-MP

418

450

428

14,400

8,055

12,500

407

427

422

12,060

14,325

12,140

468

448

463

14,684

9,549

14,590

1 mg/kg
6-MP.Pd

X

2 mg/kg
6-MP.Pd

X

*Cells per cu. mm.
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complex.

Leukocyte counts of 14,684, 9,549, and 14,590 were

recorded for the two mg/kg 6-MP palladium complex-treated
marmosets over the designated time periods.
It was recognized that the results from Experiment II did
not yield consistent data for the extent of the treatment
periods~ therefore, in an effort to evoke a more consistent
response, the dosage levels were increased (Experiment III)
based on the following:

one mg/kg 6-MP, two mg/kg 6-MP,

two mg/kg 6-MP palladium complex and four mg/kg 6-MP palladium
complex.

The results obtained in this experiment are shown in

Table 4.

The control marmosets averaged 371 gms. at initial

weighing, 395 gms. as five days of treatment , 398 gms. at 10
days and 403 grns. following a 10 day post-treatment period.
Weights of 494 gms., 496 gms., 491 gms., and 490 gms. were
recorded for the primates receiving one mg/kg 6-MP for a similar
period.

The two mg/kg 6- MP group weighted 412 gms. initially,

406 gms. at five days, 387 gms. at 10 days of treatment and 354
gtns. at the 10 day post-treatment period .

Marmosets given two

mg/kg 6-MP palladium complex registered weight averages of 334
9Ylls., 326 gms., 325., and 311 gms.

Interestingly, the weights

in the four mg/kg G-MP palladium complex experimentals
continually increased in the order 352 gms., 355 gms . , 359 gms.,
and 370 gms. for the respective treatment periods.
LeuJcocyte counts for the cont ro 1 s 1·n Experiment III over

Table 4.

Average weight and leukocyte counts (Experiment III)

(Cotton Top Species)

.

Group

Initial
10-day
5-day
Weight . Treatment . Treatment
Weight
(g)
Weight
(g)
(g)

.

.

Initial
10-day
10-day
5-day
Post
Leukocyte • Treatment
Treatment
Treatment.
count
Leukocyte. Leukocyte
weight
count*
count*
(g)

.

.

.

10-day
Post
Treatment
Leukocyte
Count*

control

371

395

398

403

12,450

12,359

11 ,100

12 ,487

1 mg/kg
6-MP

494

496

491

490

16,210

13,080

8,860

13,340

mg/kg
6-MP

412

406

387

354

13,120

12,360

9,930

9,175

2

mg/kg
6-MP.Pdx

334

326

325

311

17,910

15,820

8,480

10,830

4 mg/kg

352

355

359

370

16,260

10 ,330

4,740

9,220

2

6-MP.Pdx
*Cells per cu. mm.

N

I-'
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the given intervals averaged 12,450, 12,359, 11,100 and 12,487
respectively.
Counts of 16,210, 13,080, 8,860 and 13,340 were recorded
for the group receiving one mg/kg of 6-MP.

In the group

receiving two mg/kg 6-MP, leukocyte counts continually decreased from 13,120, 12,360, to 9,930 and down to 9,175 over
this treatment period.

The group which received two mg/kg

of 6-MP palladium complex showed 17,910 at the initial determination, 15,820 at five days, 8,480 after 10 days of treatment and 10,830 for the 10 day post treatment count.

Of

particular note were the leukocyte counts of the animals
receiving four mg/kg of 6-MP palladium complex which were
16,260, 10,830, 4,740 and 9,220, respectively for the different time intervals.
It is recognized that the wide variations in white blood
cells counts obtained warrants some explanation.

Primarily,

this was a preliminary study and the results obtained originated
from substantially insufficient number of animals.

Secondly,

more baseline data on normal leukocyte count should have preceded actual experimentation.

Saslaw (10) and Rall (lS), in

determining baseline levels established the normal leukocyte
count in monkeys to be around 10,000-15,000.

Their fi nd ings

i nd icated that excitation or excessive activity frequently
caused elevation of the leukocyte count in the neighborhood
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of 17,000 - 35,000.

Perhaps too, each animal could best serve

as his own control .

Nevertheless, the average leukocyte counts

obtained in Experiment I , II, and III conformed closely to
other established counts reported by Saslaw and Rall without
the utilization of a baseline procedure.

CHAPTER

V

SUMMARY AND CONCLUSIONS

An investigation designed to determine the feasibility
of utilizing marmosets in the study of the leukopenia-induction capacity of 6-MP palladium complex has been conducted.
Marmosets, averaging 400 gms. in weight, received doses of
6-MP or 6-MP palladium complex by oral administration daily
for different treatment periods.

Graded dosages of one, two,

three or four mg/kg of body weight were administered.

After

extensive experimentation, a method of oral administration
was utilized effectively.

Leukocyte counts were made at O

days, five days, 10 days and 10 days post-treatment.
Under the conditions of this preliminary investigation,
the following conclusions may be drawn:
(1)

Six-mercaptopurine-palladium complex may cause
a decrease in leukocyte count in marmosets at
the dosage level of four mg/kg body weight
over a 10-day treatment period.

(2)

More extensive studies based on the recommendations appended, should be conducted to
conclusively establish the leukopenia-induction
effect of the palladium complex in the marmoset.
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(3}

Leukocyte counts generally were restored to normal
during a 10-day post treatment period.

(4}

Weight changes were inconsistent in experimental
marmosets during treatment with both pure 6-MP and
its palladium complex counterpart.

(5)

Weight loss was generally restored following post
treatment.

(6)

Insertion of powdered doses of 6-MP and 6-MP
palladium complex in cross sectional slices of
bananas was an effective means of oral administration in non-human primates.

(7)

The small, squirrel-like marmoset appears to be
a suitable experimental animal for leukopenia
induction studies with 6-MP and its complexes.

CHAPTER

VI

RECOMMENDATIONS

In view of the problems encountered in the development
of original and creative techniques during the course of this
study, the following recommendations are suggested:
(1)

That most extensive investigations be conducted
utilizing experimentally significant numbers of
animals to firmly establish the leukopenia induction capacity of 6-mercaptopurine palladium
complex in hon-human primates.

(2)

That the specific role of the metallic substitution
in the reduced toxicity of these compounds should
also be investigated.

(3)

That a suitable, easily handled primate species
be used in the studies.

(4)

That ample time be allowed for familiarity and
adjustment between research personnel and
experimental animals prior to actual experimentation .

(5)

That pre-experimental studies be conducted over a
sufficient pre-treatment time period to establish
a control base reference obtained by recording of
leukocyte counts for all experimental groups which
can be utilized in a most accurate analysis of the
data.
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